GE Healthcare Recognized for CT

by Barbara Kram, Editor | March 27, 2007
NEW ORLEANS - GE Healthcare has been honored by Frost & Sullivan, a global growth consulting company, with the 2006 North American Market Leadership Award in CT for its continuing leadership in CT in North America. The award presentation was made at the 56th Annual Scientific Session of the American College of Cardiology (ACC) meeting this week in New Orleans.

Each year Frost & Sullivan presents this Award to a company that has demonstrated leadership through the implementation of market strategy.

"GE Healthcare has set the pace in CT technology with a performance unmatched by its competitors," said Frost & Sullivan industry research analyst Nadim Daher. ""Launched in 2004, GE's LightSpeed VCT helped inaugurate the concept of volumetric CT imaging and gradually shifted the discussion away from 'slice count' to 'coverage,' a more relevant clinical benchmark."

In addition, Frost and Sullivan praised GE's approach of advancing technology with a focus on clinical applications, workflow and dose efficiency.

"GE has also proven to be highly attentive to the rise of dose-consciousness among U.S. clinicians," said Daher. "Understanding that coronary CTA, an extremely important new CT application, also happened to be one of the CT examinations with the highest-relative dose, GE released the new LightSpeed VCT XT version that offers as much as a 70 percent dose reduction with uncompromised image quality."

According to Frost & Sullivan, GE's focus on developing new technologies speaks to a long-term vision for the scope and capabilities of medical science in the future.

"This award is a testament to GE's commitment to healthcare," said Gene Saragnese, vice president and general manager of GE Healthcare's CT and
Molecular Imaging business. "As leaders in CT, we continue to focus on developing technologies that provide clinical excellence and outstanding image quality. This vision is helping shift the global paradigm of healthcare to early prevention of disease, as opposed to late diagnosis and treatment."

ABOUT GE HEALTHCARE

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.
For more information about GE Healthcare, visit our website at www.gehealthcare.com .